Covid-19 Research

Mini Review

Current Stem Cell Research Status on Hepatic and Pulmonary Sclerosis in COVID-19

Journal of Biomedical Research & Environmental Sciences article abstract with citation details, DOI, publication dates, subject areas, full text links, and references.

View DOI Submit Manuscript

Article Details

Publication record, authors, dates, abstract, and full text access.

Open Access
Article Type Mini Review
Subject Biology Group
OCLC 9041817376
Jeongryun Kim, Soo Hyun Nam2,3, Jong Hyun Kim* and Jiyou Han*
Issue: Volume2-Issue4
Pages: 292-295
Received: 2021-04-16
Accepted: 2021-04-21
Published: 2021-04-22

Abstract

Since 2019, Coronavirus Disease (COVID-19) has changed the concept of systemic sclerosis caused by viral infectious diseases. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative organism of COVID-19, has infected more than 1.36 billion people in 188 countries, and nearly 2.29 million have died. Although we have rapidly developed vaccines against COVID-19, the struggle to treat COVID-19 patients who exhibit complicated multiple organ sclerosis has continued ever since. Studies have reported that preexisting liver disease in 3-8% of patients increases metabolic dysfunction and mortality by 4-6-fold in association with the severity of COVID-19. Moreover, both confirmed and cured COVID-19 patients have been reported to develop pulmonary fibrosis, which is often related to poor prognosis of the complications. Therefore, in the present study, we summarize the possible mechanisms underlying the development of hepatic and pulmonary fibrosis caused by SARS-CoV-2 infection, based on recently published data. Furthermore, since stem cell-based treatments have been developed as a novel approach to treat COVID-19 patients with Systemic Sclerosis (SS), we discuss the implementation of stem cell-based treatments as a powerful regenerative tool owing to their notable immunomodulatory and anti-fibrotic effects.

FullText HTML FullText PDF DOI: 10.37871/jbres1228 Crossmark

Certificate of Publication

Certificate of Publication

Copyright

© 2021 Kim J, et al. Distributed under Creative Commons CC-BY 4.0 Creative CommonsAttribution

How to cite this article

Kim J, Nam SH, Kim JH, Han J. Current Stem Cell Research Status on Hepatic and Pulmonary Sclerosis in COVID-19. J Biomed Res Environ Sci. 2021 Apr 22; 2(4): 292-295. doi: 10.37871/jbres1228, Article ID: jbres1228

Subject area(s)

BiologyInfectious DiseasesVirology

References

  1. Han W, Quan B, Guo Y, Zhang J, Lu Y, Feng G, Wu Q, Fang F, Cheng L, Jiao N, Li X, Chen Q. The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019. J Med Virol. 2020 May;92(5):461-463. doi: 10.1002/jmv.25711. Epub 2020 Mar 1. PMID: 32073161; PMCID: PMC7167012.
  2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24. PMID: 31978945; PMCID: PMC7092803.
  3. V’kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021 Mar;19(3):155-170. doi: 10.1038/s41579-020-00468-6. Epub 2020 Oct 28. PMID: 33116300; PMCID: PMC7592455.
  4. Wu F, Zhao S, Yu B, Chen YM, Wang W, Hu Y, et al. Complete genome characterisation of a novel coronavirus associated with severe human respiratory disease in Wuhan, China. BioRxiv. 2020. doi:10.1101/2020.01.24.919183.
  5. Wu HT, Chuang YW, Huang CP, Chang MH. Loss of angiotensin converting enzyme II (ACE2) accelerates the development of liver injury induced by thioacetamide. Exp Anim. 2018 Feb 9;67(1):41-49. doi: 10.1538/expanim.17-0053. Epub 2017 Aug 25. PMID: 28845018; PMCID: PMC5814313.
  6. Kuba K, Imai Y, Penninger JM. Angiotensin-converting enzyme 2 in lung diseases. Curr Opin Pharmacol. 2006 Jun;6(3):271-6. doi: 10.1016/j.coph.2006.03.001. Epub 2006 Apr 3. PMID: 16581295; PMCID: PMC7106490.
  7. Ni W, Yang X, Yang D, Bao J, Li R, Xiao Y, Hou C, Wang H, Liu J, Yang D, Xu Y, Cao Z, Gao Z. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care. 2020 Jul 13;24(1):422. doi: 10.1186/s13054-020-03120-0. PMID: 32660650; PMCID: PMC7356137.
  8. Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, Raizada MK, Grant MB, Oudit GY. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res. 2020 May 8;126(10):1456-1474. doi: 10.1161/CIRCRESAHA.120.317015. Epub 2020 Apr 8. PMID: 32264791; PMCID: PMC7188049.
  9. Li D, Ding X, Xie M, Tian D, Xia L. COVID-19-associated liver injury: from bedside to bench. J Gastroenterol. 2021 Mar;56(3):218-230. doi: 10.1007/s00535-021-01760-9. Epub 2021 Feb 1. PMID: 33527211; PMCID: PMC7849620.
  10. Warner FJ, Rajapaksha H, Shackel N, Herath CB. ACE2: from protection of liver disease to propagation of COVID-19. Clin Sci (Lond). 2020 Dec 11;134(23):3137-3158. doi: 10.1042/CS20201268. PMID: 33284956.
  11. McVicker BL, Bennett RG. Novel Anti-fibrotic Therapies. Front Pharmacol. 2017 May 31;8:318. doi: 10.3389/fphar.2017.00318. PMID: 28620300; PMCID: PMC5449464.
  12. Haldar D, Henderson NC, Hirschfield G, Newsome PN. Mesenchymal stromal cells and liver fibrosis: a complicated relationship. FASEB J. 2016 Dec;30(12):3905-3928. doi: 10.1096/fj.201600433R. Epub 2016 Sep 6. PMID: 27601441.
  13. Xing L, Chang X, Shen L, Zhang C, Fan Y, Cho C, Zhang Z, Jiang H. Progress in drug delivery system for fibrosis therapy. Asian J Pharm Sci. 2021 Jan;16(1):47-61. doi: 10.1016/j.ajps.2020.06.005. Epub 2020 Jul 17. PMID: 33613729; PMCID: PMC7878446.
  14. Ruiz-Velascoa JA, Aldana-Ledesma JM, Ibarra-Estrada MA, Aguirre Díazc SA, Fernández-Ramírez JA, Cárdenas-Lara F, et al. Revista de Gastroenterología de México. 2017;82:301-308. doi: 10.1016/j.rgmxen.2017.08.002.
  15. Chai X, Hu L, Zhang Y, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. biorxiv Preprint 4 February 2020. doi: 10.1101/2020.02.03.931766.
  16. Zhao B, Ni C, Gao R, Wang Y, Yang L, Wei J, Lv T, Liang J, Zhang Q, Xu W, Xie Y, Wang X, Yuan Z, Liang J, Zhang R, Lin X. Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids. Protein Cell. 2020 Oct;11(10):771-775. doi: 10.1007/s13238-020-00718-6. PMID: 32303993; PMCID: PMC7164704.
  17. Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020 May;40(5):998-1004. doi: 10.1111/liv.14435. Epub 2020 Mar 30. PMID: 32170806; PMCID: PMC7228361.
  18. Alqahtani SA, Schattenberg JM. Liver injury in COVID-19: The current evidence. United European Gastroenterol J. 2020 Jun;8(5):509-519. doi: 10.1177/2050640620924157. PMID: 32450787; PMCID: PMC7268949.
  19. Piersma B, Bank RA, Boersema M. Signaling in Fibrosis: TGF-β, WNT, and YAP/TAZ Converge. Front Med (Lausanne). 2015 Sep 3;2:59. doi: 10.3389/fmed.2015.00059. PMID: 26389119; PMCID: PMC4558529.
  20. Mares J, Hartung HP. Multiple sclerosis and COVID-19. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020 Sep;164(3):217-225. doi: 10.5507/bp.2020.033. Epub 2020 Jul 17. PMID: 32686774.
  21. Choudhery MS, Harris DT. Stem cell therapy for COVID-19: Possibilities and challenges. Cell Biol Int. 2020 Nov;44(11):2182-2191. doi: 10.1002/cbin.11440. Epub 2020 Aug 22. PMID: 32767687; PMCID: PMC7436138.
  22. Li Z, Niu S, Guo B, Gao T, Wang L, Wang Y, Wang L, Tan Y, Wu J, Hao J. Stem cell therapy for COVID-19, ARDS and pulmonary fibrosis. Cell Prolif. 2020 Dec;53(12):e12939. doi: 10.1111/cpr.12939. Epub 2020 Oct 24. PMID: 33098357; PMCID: PMC7645923.
  23. Jayaramayya K, Mahalaxmi I, Subramaniam MD, Raj N, Dayem AA, Lim KM, Kim SJ, An JY, Lee Y, Choi Y, Raj A, Cho SG, Vellingiri B. Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cell-derived exosomes for COVID-19 treatment. BMB Rep. 2020 Aug;53(8):400-412. doi: 10.5483/BMBRep.2020.53.8.121. PMID: 32731913; PMCID: PMC7473478.
  24. Kim MD, Kim SS, Cha HY, Jang SH, Chang DY, Kim W, Suh-Kim H, Lee JH. Therapeutic effect of hepatocyte growth factor-secreting mesenchymal stem cells in a rat model of liver fibrosis. Exp Mol Med. 2014 Aug 22;46(8):e110. doi: 10.1038/emm.2014.49. PMID: 25145391; PMCID: PMC4150933.
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership